

ESC Declaration of Interest Report

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes

The ESC reviews relationships with industry and encourages transparency and ethical integrity.

It is mandatory for all experts involved in the development of ESC Guidelines to comply with the ESC Declaration and Management of Conflict of Interest Policy. Under this policy, they are required to submit yearly Declaration of Interest (DOI) forms during the writing and reviewing phases of the Guidelines.

All DOIs presented in this report were assessed prior to work commencing and during the development of the work, according to the applicable review criteria in place at the time and as defined in the ESC Declaration and Management of Conflict of Interest Policy, Annex 3.

The most up-to-date version of the policy and its annexes are available on the ESC website at www.escardio.org/DOI.

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Ajjan Ramzi	<p>2020</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Boehringer-Ingelheim : Cardiac health and SGLT2i Astra Zeneca : Cardiovascular disease in diabetes Novo-Nordisk : Diabetes and cardiovascular risk Eli Lilly : Diabetes, glycaemic management and CV risk Abbott : Glycaemic management in diabetes</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Abbott : Diabetes and glycaemia</p>
	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Boehringer-Ingelheim : Cardiac health and SGLT2i Astra Zeneca : Cardiovascular disease in diabetes Novo-Nordisk : Diabetes and cardiovascular risk Eli Lilly : Diabetes, glycaemic management and CV risk Abbott : Glycaemic management in diabetes</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Abbott : Diabetes and glycaemia</p>
	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Boehringer-Ingelheim : Cardiovascular Disease in Special Populations Eli Lilly : Cardiovascular Disease in Special Populations, Other Astra Zeneca : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS), Cardiovascular Disease in Special Populations, Other Abbott : Other Novo-Nordisk : Pharmacology and Pharmacotherapy</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Abbott : Investigator-led clinical studies as well as industry-led clinical work, Chief investigator or PI</p>

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry	
Antunes Manuel	2020	Nothing to be declared
	2021	Nothing to be declared
	2022	Nothing to be declared
Christodorescu Ruxandra Maria	2020	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Servier : Hypertension Pfizer : Thrombosis Boeringer Ingelheim : Thrombosis</p>
	2021	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Pfizer : Antithrombotic Therapy Viatrix : Dyslipidemia Servier : Heart Failure Boehringer-Ingelheim : Heart Failure Pharmacotherapy Travel and meeting support from healthcare industry, independent of the above activities. Servier : Interventional Cardiology</p>
	2022	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Pfizer : Atrial Fibrillation (AF) Astra Zeneca : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Zentiva : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Servier : Hypertension Viatrix : Risk Factors and Prevention Travel and meeting support from healthcare industry, independent of the above activities. Novartis : Chronic Heart Failure</p>

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry	
Crawford Carolyn	2020	Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology. Member of ESC Patients' Forum
	2021	Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology. Member of ESC Patients' Forum
	2022	Nothing to be declared
Di Angelantonio Emanuele	2020	Nothing to be declared
	2021	Nothing to be declared
	2022	Nothing to be declared
Eliasson Bjorn	2020	Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : diabetes Boehringer-Ingelheim : diabetes Eli Lilly : diabetes Sanofi Aventis : diabetes Merck Sharp & Dohme : diabetes Novo-Nordisk : Diabetes Bayer AG : diabetes
	2021	Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : diabetes Boehringer-Ingelheim : diabetes Eli Lilly : diabetes Sanofi Aventis : diabetes Merck Sharp & Dohme : diabetes Novo-Nordisk : Diabetes Bayer AG : diabetes

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Eliasson Bjorn	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Eli Lilly : Pharmacology and Pharmacotherapy Sanofi Aventis : Pharmacology and Pharmacotherapy Novo-Nordisk : Pharmacology and Pharmacotherapy Bayer AG : Pharmacology and Pharmacotherapy</p>
Espinola-Klein Christine	<p>2020</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bayer Health Care : Anticoagulants Pfizer : Antikoagulation Bristol Myers Squibb : Antikoagulation Boehringer Ingelheim : Diabetes Amgen : Lipid lowering medication Daiichi Sankyo : Lipid lowering medication</p> <hr style="border-top: 1px dashed black;"/> <p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bayer Health Care : Anticoagulants Pfizer : Antikoagulation Bristol Myers Squibb : Antikoagulation Boehringer Ingelheim : Diabetes Amgen : Lipid lowering medication Daiichi Sankyo : Lipid lowering medication Sanofi Aventis : Lipid lowering medication Amarin : Lipid lowering medication Cordis : peripheral intervention</p>

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Espinola-Klein Christine	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Amgen : Peripheral Vascular and Cerebrovascular Disease Boehringer-Ingelheim : Peripheral Vascular and Cerebrovascular Disease Daiichi Sankyo : Peripheral Vascular and Cerebrovascular Disease Novartis : Peripheral Vascular and Cerebrovascular Disease Pfizer : Peripheral Vascular and Cerebrovascular Disease Sanofi Aventis : Peripheral Vascular and Cerebrovascular Disease Bristol Myers Squibb : Peripheral Vascular and Cerebrovascular Disease Amarin : Peripheral Vascular and Cerebrovascular Disease</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. German Society of Cardiology, German Society of Angiology, German Society of Internal Medicine, Society of Thrombosis and Haemostasis</p>
Fauchier Laurent	<p>2020</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bayer : Healthcare Boehringer-Ingelheim : Healthcare Medtronic : Healthcare Novartis : Healthcare BMS/Pfizer : Healthcare XO : Healthcare</p>

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Fauchier Laurent	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Healthcare Bayer : Healthcare Boehringer-Ingelheim : Healthcare Medtronic : Healthcare Novartis : Healthcare BMS/Pfizer : Healthcare Novo-Nordisk : Healthcare Zoll Medical : Healthcare XO : Healthcare</p>
	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Pharmacology and Pharmacotherapy Bayer : Pharmacology and Pharmacotherapy Boehringer-Ingelheim : Pharmacology and Pharmacotherapy Novartis : Pharmacology and Pharmacotherapy Servier : Pharmacology and Pharmacotherapy BMS/Pfizer : Pharmacology and Pharmacotherapy Novo-Nordisk : Pharmacology and Pharmacotherapy</p>
Federici Massimo	<p>2020</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Lilly : diabetes Merck Sharp & Dohme : diabetes Boehringer Ingelheim : diabetes Amgen Inc : metabolic syndrome</p>

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Federici Massimo	<p>2021 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Lilly : Diabetes (speaker fee) Amarin : Dyslipidemia (advisory board fee) Amgen : Dyslipidemia, Metabolic Syndrome, Psoriasis (speaker fees)</p> <hr/> <p>2022 Nothing to be declared</p>
Halle Martin	<p>2020 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Roche Pharma : Cancer Abbott : Diabetes Novo-Nordisk : Diabetes</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology. German Society of Prevention and Rehabilitation of Cardiovascular Disease (DGPR), voluntary work Kuratorium für Prävention und Rehabilitation von Herz-Kreislauf-erkrankungen (local organisation of rehabilitation groups), voluntary work German Society of Cardiology (DGK), working group member in sports cardiology, preventive cardiology, voluntary work</p> <hr/> <p>2021 Employment in healthcare industry (including part time) during the year for which you are declaring. Advisor for a Rehabilitation Clinic Consortium (Medical Park SE, Amerang, Germany); no involvement in medical therapy</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology. Member German Society of Cardiology</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. Head of the funding board of the German Association of Cardiovascular Prevention and Rehabilitation (honorary, non-financial)</p>

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Halle Martin	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Abbott : Rehabilitation and Sports Cardiology Amgen : Rehabilitation and Sports Cardiology Boehringer-Ingelheim : Rehabilitation and Sports Cardiology Daiichi Sankyo : Rehabilitation and Sports Cardiology Pfizer : Rehabilitation and Sports Cardiology Roche Pharma : Rehabilitation and Sports Cardiology Bristol Myers Squibb : Rehabilitation and Sports Cardiology</p> <p>Employment (including part time) in healthcare industry during the year for which you are declaring. Medical Park Rehabilitation group : medical advisor</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. Past President EAPC</p>
Herrington William	<p>2020</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Boehringer-Ingelheim : kidney disease, SGLT-2 inhibition Lilly : kidney disease, SGLT-2 inhibition</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. UK Kidney Association Clinical Practice Guideline on SGLT-2 inhibitor use in adults with chronic kidney disease (co-chair)</p>
	<p>2021</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Boehringer-Ingelheim : kidney disease, SGLT-2 inhibition Lilly : kidney disease, SGLT-2 inhibition</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. UK Kidney Association Clinical Practice Guideline on SGLT-2 inhibitor use in adults with chronic kidney disease (co-chair)</p>
	<p>2022</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Boehringer-Ingelheim : EMPA-KIDNEY and other trial work, Chief Investigator Lilly : EMPA-KIDNEY trial, Chief Investigator</p>
Kautzky-Willer Alexandra	<p>2020</p> <p>Nothing to be declared</p>

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry	
Kautzky-Willer Alexandra	2021	Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Diabetes Boehringer-Ingelheim : Diabetes Lilly : Insulin Amgen : Lipids Novo-Nordisk : Obesity
	2022	Nothing to be declared
Lambrinou Ekaterini	2020	Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Novartis : Heart Failure
	2021	Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. European Society of Cardiology : ACNAP Injectables in Cardiovascular disease
	2022	Nothing to be declared

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Lesiak Maciej	<p>2020</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Amgen : Speaker fees Bayer : Speaker fees Boehringer-Ingelheim : Speaker fees Boston Scientific : Speaker fees Medtronic : Speaker fees Novartis : Speaker fees Pfizer : Speaker fees Servier : Speaker fees Biotronik : Speaker fees Terumo Inc : Speaker fees Siemens Healthcare : Speaker fees Abbott Vascular : Speaker fees Astra Zeneca : Speaker fees, Advisory Board Member</p> <p>Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease. Healthcare - ALL AREAS OF CARDIOLOGY - Minor shares of two Polish companies providing medical in-hospital service in interventional cardiology Education - Minor shares of the local, regional company operating in the medical education field</p>

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Lesiak Maciej	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Berlin Menarini : Advisory board Astra Zeneca : Speaker fees Bayer : Speaker fees Boehringer-Ingelheim : Speaker fees Boston Scientific : Speaker fees Medtronic : Speaker fees Novartis : Speaker fees Pfizer : Speaker fees Philips : Speaker fees Biotronik : Speaker fees Terumo Inc : Speaker fees Sanofi Aventis : Speaker fees Abbott Vascular : Speaker fees Merck Sharp & Dohme : Speaker fees</p> <p>Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease. Healthcare - ALL AREAS OF CARDIOLOGY - Minor shares of one Polish company providing medical in-hospital service in interventional cardiology Education - Minor shares of the local, regional company operating in the medical education field</p>

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Lesiak Maciej	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <p>Bayer : Atrial Fibrillation (AF)</p> <p>Boehringer-Ingelheim : Atrial Fibrillation (AF)</p> <p>Pfizer : Atrial Fibrillation (AF), Acute Coronary Syndromes</p> <p>Novartis : Chronic Heart Failure</p> <p>Astra Zeneca : Chronic Heart Failure, Acute Coronary Syndromes</p> <p>Boston Scientific : Interventional Cardiology</p> <p>Medtronic : Interventional Cardiology</p> <p>Philips : Interventional Cardiology</p> <p>Biotronik : Interventional Cardiology</p> <p>Terumo Inc : Interventional Cardiology</p> <p>Abbott Vascular : Interventional Cardiology</p> <p>Sanofi Aventis : Pharmacology and Pharmacotherapy</p>
Lettino Maddalena	<p>2020</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <p>Daiichi Sankyo : anticoagulants</p> <p>Pfizer : anticoagulants</p> <p>Bristol Myers Squibb : anticoagulants</p> <p>Boehringer-Ingelheim : clinical research and drug approval from regulatory agencies</p> <p>Sanofi Aventis : lipid-lowering drugs</p>

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Lettino Maddalena	<p>2021 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Boehringer-Ingelheim : anticoagulants Pfizer : anticoagulants Bristol Myers Squibb : anticoagulants Sanofi Aventis : antithrombotic agents and lipid-lowering drugs Edwards Lifesciences : percutaneous cardiac devices</p> <hr/> <p>2022 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bristol Myers Squibb : Atrial Fibrillation (AF), Pharmacology and Pharmacotherapy Novartis : Risk Factors and Prevention Amarin : Risk Factors and Prevention</p>
Marx Nikolaus	<p>2020 Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bayer : Anticoagulants Astra Zeneca : Diabetes Novo-Nordisk : Diabetes MSD : Diabetes Boehringer Ingelheim / Lilly : Diabetes Genfit SA : NASH</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Boehringer-Ingelheim : Diabetes MSD : Diabetes</p>

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Marx Nikolaus	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bayer : Anticoagulants Astra Zeneca : Diabetes Boehringer-Ingelheim : Diabetes Novo-Nordisk : Diabetes</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bayer : Anticoagulants Abbott : Diabetes Astra Zeneca : Diabetes Bristol Myers Squibb : Diabetes Novo-Nordisk : Diabetes MSD : Diabetes Boehringer Ingelheim / Lilly : Diabetes Sanofi Aventis : Lipids Genfit SA : NASH</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Boehringer-Ingelheim : Diabetes MSD : Diabetes</p>
	<p>2022</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Other Bayer : Other Novo-Nordisk : Other MSD : Other Boehringer Ingelheim / Lilly : Other</p>

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
McGuire Darren Keith	<p>2020</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Boehringer-Ingelheim : diabetes</p> <p>Research funding (personal) from healthcare industry. Boehringer-Ingelheim : diabetes</p> <p>Employment in healthcare industry (including part time) during the year for which you are declaring. Faculty-University of Texas Southwestern Medical Center</p>
	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Boehringer-Ingelheim : diabetes</p> <p>Research funding (personal) from healthcare industry. Boehringer-Ingelheim : diabetes</p> <p>Employment in healthcare industry (including part time) during the year for which you are declaring. Faculty-University of Texas Southwestern Medical Center</p>

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
McGuire Darren Keith	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Altathera : History of Cardiology, Ventricular Arrhythmias and Sudden Cardiac Death (SCD) Bayer : Risk Factors and Prevention Boehringer-Ingelheim : Risk Factors and Prevention Lilly : Risk Factors and Prevention Novo-Nordisk : Risk Factors and Prevention CSL Behring : Risk Factors and Prevention Intercept : Risk Factors and Prevention Esperion : Risk Factors and Prevention Applied Therapeutics : Risk Factors and Prevention Lexicon : Risk Factors and Prevention Altimmune : Risk Factors and Prevention</p> <p>Research funding (personal) from healthcare industry. Esperion : national lead investigator, national lead investigator Novo Nordisk : trial chair, trial chair Astra Zeneca : trial executive committee, trial executive committee Lilly : trial executive committee, trial executive committee Pfizer : trial IDMC, trial IDMC CSL Behring : trial IDMC, trial IDMC</p> <p>Employment (including part time) in healthcare industry during the year for which you are declaring. University of Texas Southwestern Medical Center : Professor</p>

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Mueller-Wieland Dirk	<p>2020</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Boehringer-Ingelheim : diabetes Sanofi Aventis : Diabetes Lilly : Diabetes Merck Sharp & Dohme : diabetes Astrazeneca : diabetes Amgen : lipids Novartis : lipids Amarin : lipids Sanofi-Pasteur : vaccination</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology. German Diabetes Association, DACH organisation for prevention of CVD, German Society of Cardiology, German Society of Internal Medicine, International Task Force for Prevention of Cardiovascular Disease</p>

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Mueller-Wieland Dirk	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <p>Astra Zeneca : diabetes</p> <p>Boehringer-Ingelheim : Diabetes</p> <p>Pfizer : diabetes</p> <p>Sanofi Aventis : diabetes</p> <p>Lilly : diabetes</p> <p>Merck Sharp & Dohme : Diabetes</p> <p>Novo-Nordisk : diabetes</p> <p>Bayer AG : diabetes</p> <p>Amgen : lipids</p> <p>Daiichi Sankyo : lipids</p> <p>Novartis : lipids</p> <p>Amarin : lipids</p>

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Mueller-Wieland Dirk	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Boehringer-Ingelheim : Chronic Heart Failure Astra Zeneca : Other Pfizer : Other Sanofi Aventis : Other Lilly : Other Novo-Nordisk : Other Bayer AG : Other Amgen : Risk Factors and Prevention Daiichi Sankyo : Risk Factors and Prevention Novartis : Risk Factors and Prevention Merck Sharp & Dohme : Risk Factors and Prevention Amarin : Risk Factors and Prevention</p>
Mullens Wilfried	<p>2020</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Pfizer : consultancy Astra Zeneca : speaker fees Medtronic : speaker fees Boehringer-Ingelheim : speakers fees</p> <hr/> <p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Medtronic : consultancy fee Vifor International : research grant Abbott : speakers fee Boston Scientific : speakers fee Novartis : speakers fee</p>

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry	
Mullens Wilfried	2022	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Abbott : Training and Education Astra Zeneca : Training and Education Medtronic : Training and Education Novartis : Training and Education Biotronik : Training and Education Novo-Nordisk : Training and Education dynacom : Training and Education</p>
Rocca Bianca	2020	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bayer AG : antiplatelet Novartis : haematology</p>
	2021	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bayer AG : CV prevention in COVID pandemics SOBI : platelet growth factor</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Bayer AG : anticoagulant (rivaroxaban)</p>
	2022	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Aboca SRL : Other</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Bayer AG : study on low dose rivaroxaban, Chief investigator</p>

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Sattar Naveed	<p>2020</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Boehringer-Ingelheim : diabetes Eli Lilly : diabetes Merck Sharp & Dohme : diabetes Novo-Nordisk : diabetes Novartis : lipids Sanofi Aventis : lipids and diabetes</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : diabetes Boehringer-Ingelheim : diabetes Eli Lilly : diabetes Pfizer : diabetes Sanofi Aventis : diabetes Novo-Nordisk : diabetes Amgen : lipids</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Boehringer-Ingelheim : diabetes</p>

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Sattar Naveed	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Afimmune : CVD and diabetes Novo-Nordisk : diabetes Sanofi Aventis : lipids and diabetes</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Boehringer-Ingelheim : diabetes Eli Lilly : diabetes Pfizer : diabetes Sanofi Aventis : diabetes Novo-Nordisk : diabetes Astrazeneca : diabetes Hanmi Pharmaceuticals : diabetes Amgen : lipids</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Roche Diagnostics : Cardiac biomarkers Novartis : CVD Boehringer-Ingelheim : diabetes Astrazeneca : diabetes</p>

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Sattar Naveed	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Novo Nordisk : Other Novartis : Risk Factors and Prevention, Other Roche Diagnostics : Risk Factors and Prevention, Other</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Other Boehringer-Ingelheim : Other Eli Lilly : Other Pfizer : Other Novo Nordisk : Other Amgen : Risk Factors and Prevention, Other Abbott Laboratories : Risk Factors and Prevention, Other</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Astra Zeneca : Co-Lead on Biomarkers in DAPA-HF Trial, Co-lead Boehringer-Ingelheim : Investigator initiated grant SUGAR-DM-HF, Chief Investigator</p>
Schuett Katharina	<p>2020</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Lilly : Advisory board fee Novo-Nordisk : Speaker Fee MSD : Speaker Fee Sciarc : Speaker Fee Diaplan : Speaker Fee Bayer : Speaker Fees and advisory board fees Boehringer-Ingelheim : Speaker Fees and advisory board fees Astrazeneca : Speaker Fees and advisory board fees</p>

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Schuett Katharina	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Lilly : Adivsory board fee Novo-Nordisk : Speaker Fee Bayer : Speaker Fees and advisory board fees Boehringer-Ingelheim : Speaker Fees and advisory board fees Astrazeneca : Speaker Fees and advisory board fees</p>
	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Boehringer-Ingelheim : Chronic Heart Failure Astrazeneca : Chronic Heart Failure Amgen : Risk Factors and Prevention Bayer : Risk Factors and Prevention Novo-Nordisk : Risk Factors and Prevention MSD : Risk Factors and Prevention</p>

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Abdelhamid Magdy	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bayer AG : Advisory board fees Astra Zeneca : speaker fees Boehringer-Ingelheim : speaker fees Novartis : speaker fees</p>
	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bayer AG : Chronic Heart Failure</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Pfizer : Grant for the cardiology department Cairo University for research project : Screening for cardiac amyloidosis in patients with unexplained LVH , Principal investigator</p>
Aboyans Victor	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bayer Healthcare : Antithrombotic therapies Novo-Nordisk : Diabetes Astrazeneca : Diabetes Boehringer Ingelheim : Diabetes</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology. Member of the French Society of Cardiology</p>
	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astrazeneca : Chronic Heart Failure Bayer Healthcare : Peripheral Vascular and Cerebrovascular Disease, Risk Factors and Prevention Novo-Nordisk : Risk Factors and Prevention Amarin : Risk Factors and Prevention Boehringer Ingelheim : Risk Factors and Prevention</p>

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Aboyans Victor	2022 Membership or affiliation in political or advocacy groups working in the field of cardiology. I am a board member of the French Society of Cardiology, and the French Federation of Cardiology
Agathangelou Petros	2021 Nothing to be declared
	2022 Nothing to be declared
Antoniou Sotiris	2021 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Pfizer : speaker fees for education - AF Bayer AG : speaker fees for education - AF Daiichi Sankyo : speaker fees for education -AF Astra Zeneca : speaker fees for education - CVD Boehringer-Ingelheim : speaker fees for education - CVD Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Astra Zeneca : Joint working initiative on improving CV care Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology. Member of Arrhythmia alliance medical advisory panel
	2022 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Pfizer : Atrial Fibrillation (AF) Bayer AG : Atrial Fibrillation (AF), Acute Coronary Syndromes Boehringer-Ingelheim : Atrial Fibrillation (AF), Chronic Heart Failure Daiichi Sankyo : Atrial Fibrillation (AF), Pharmacology and Pharmacotherapy Astra Zeneca : Chronic Heart Failure Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Amarin : development of post MI virtual follow up, Lead investigator Novartis : joint working collaboration on CVD prevention , principal lead
Asteggiano Riccardo	2021 Receipt of royalties for intellectual property. Council of Cardio-Oncology ESC : cardio-oncology

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry	
Asteggiano Riccardo	2022	Nothing to be declared
Badariene Jolita	2021	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Amgen : Clinical trial, principal investigator Boehringer-Ingelheim : Fees for lectures Servier : Fees for lectures Krka Pharma : Fees for lectures Novartis : Fees for lectures, Advisory board fees,</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Amgen : Clinical trial</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Amgen : Payment of the conference registration fees Novartis : Payment of the conference registration fees Servier : Payment of the conference registration fees</p>
	2022	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Berlin Menarini : Hypertension Amgen : Other Novartis : Risk Factors and Prevention Servier : Risk Factors and Prevention Krka Pharma : Risk Factors and Prevention</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Novartis : Other Krka Pharma : Other</p>

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Banu Cristiana	2021 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Daiichi Sankyo : Atrial Fibrillation Pfizer : Atrial Fibrillation Bayer : Atrial fibrollation Boehringer-Ingelheim : Diabetes
	2022 Nothing to be declared
Baumgartner Iris	2021 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Boston Scientific : Advisoty Board Daiichi Sankyo : Lipid lowering Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Terumo Inc : Educational Grant Abbott Vascular : Educational Grant Boston Scientific : Research Grant Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Terumo Inc : Research Grant
	2022 Declaration not submitted
Beleslin Branko	2021 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Alkaloid : antithrombitic therapy
	2022 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Krka Pharma : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Abella Pharm : Rehabilitation and Sports Cardiology
Bosevski Marijan	2021 Nothing to be declared
	2022 Nothing to be declared

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Boskovic Aneta	2021 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bayer : Atrial fibrillation Astra Zeneca : Heart failure Boehringer-Ingelheim : Heart failure
	2022 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Boehringer-Ingelheim : Atrial Fibrillation (AF) Bayer : Atrial Fibrillation (AF), Pharmacology and Pharmacotherapy Astra Zeneca : Chronic Heart Failure
Bsata Walid	2021 Nothing to be declared
	2022 Nothing to be declared
Buccheri Sergio	2021 Nothing to be declared
	2022 Nothing to be declared
Bueno Hector	2021 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. MEDSCAPE-the heart.org : General (antithrombotics, vaccines) Astra Zeneca : Heart Failure: Observational studies on use of healthcare resources and economic costs Novartis : Sacubitril-valsartan Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Bayer : Antithrombotics PhaseBio : Antithrombotics Astrazeneca : Heart Failure Boehringer Ingelheim : Heart Failure Novartis : Heart Failure - Sacubitril-valsartan Research funding (personal) from healthcare industry. Bayer : New antithrombotics: PACIFIC-MI Trial

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Bueno Hector	<p>2021 Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology. Advisor and Scientific Director, National Strategy on Cardiovascular Health. Ministry of Health and Welfare. Spain's Government Vicepresident. Spanish Society of Cardiology (Until Oct 2021)</p> <hr/> <p>2022 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Organon : Cardiovascular Disease in Special Populations Astra Zeneca : Chronic Heart Failure Novartis : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Novo-Nordisk : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Boehringer-Ingelheim : EMPACT-MI (EMPAGliflozin vs placebo in patients with AMI), PI Janssen-Cilag : PACIFIC-MI (Phase 2 RCT milvexian vs placebo following an AMI), PI Novartis : PARADISE-MI (RCT Sacubitril-valsartan vs ramipril post-AMI), Principal investigator Astrazeneca : The Clinical Outcomes, HEalthcare REsource Utilization, and relaTed costs (COHERENT) – Heart Failure and COPD Project, Lead investigator, COHERENT</p>
Burchardt Pawel	<p>2021 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bayer : Anticoagulation Amgen : Dyslipidemia Sanofi Aventis : Dyslipidemia Teva Pharmaceutical Industries : Dyslipidemia Novartis : Dyslipidemia, Heart Failure</p>

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Burchardt Pawel	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bayer : Atrial Fibrillation (AF) Sanofi Aventis : Risk Factors and Prevention, Training and Education Amgen : Training and Education Novartis : Training and Education</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Pfizer : European Society of Cardiology</p>
Bytyci Ibadete	<p>2021 Nothing to be declared</p> <p>2022 Nothing to be declared</p>
Carballo David	<p>2021</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Amgen : Atherosclerosis Boehringer-Ingelheim : Heart Failure Servier : Heart Failure</p> <p>2022</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Boehringer Ingelheim (Schweiz) GmbH : Chronic Heart Failure</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Pfizer : European Society of Cardiology</p>

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Castro Conde Almudena	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Novartis : Cardiovascular: Diabetes, Obesity, Heart Failure, Women and CV disease, Coronary disease Astra Zeneca : Cardiovascular: Diabetes, Obesity, Heart Failure, Women and CV disease, Coronary disease Boehringer-Ingelheim : Cardiovascular: Diabetes, Obesity, Heart Failure, Women and CV disease, Coronary disease Lilly : Cardiovascular: Diabetes, Obesity, Heart Failure, Women and CV disease, Coronary disease Esteve : Cardiovascular: Diabetes, Obesity, Heart Failure, Women and CV disease, Coronary disease Merck Sharp & Dohme : Cardiovascular: Diabetes, Obesity, Heart Failure, Women and CV disease, Coronary disease Novo-Nordisk : Cardiovascular: Diabetes, Obesity, Heart Failure, Women and CV disease, Coronary disease Organon : Cardiovascular: Diabetes, Obesity, Heart Failure, Women and CV disease, Coronary disease</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Novo-Nordisk : SELECT trial Lilly : Surpass-COVT trial</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology. Diabetes and Obesity working group o Spanish Society of cardiology coordinator</p>

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Castro Conde Almudena	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Organon : 6 items checked</p> <p>Astra Zeneca : Chronic Heart Failure, Acute Heart Failure, Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS), Risk Factors and Prevention, Rehabilitation and Sports Cardiology</p> <p>Boehringer-Ingelheim : Chronic Heart Failure, Acute Heart Failure, Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS), Risk Factors and Prevention, Rehabilitation and Sports Cardiology</p> <p>Novartis : Chronic Heart Failure, Acute Heart Failure, Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS), Risk Factors and Prevention, Rehabilitation and Sports Cardiology</p> <p>Lilly : Chronic Heart Failure, Acute Heart Failure, Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS), Risk Factors and Prevention, Rehabilitation and Sports Cardiology</p> <p>Esteve : Chronic Heart Failure, Acute Heart Failure, Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS), Risk Factors and Prevention, Rehabilitation and Sports Cardiology</p> <p>Merck Sharp & Dohme : Chronic Heart Failure, Acute Heart Failure, Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS), Risk Factors and Prevention, Rehabilitation and Sports Cardiology</p> <p>Novo-Nordisk : Chronic Heart Failure, Acute Heart Failure, Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS), Risk Factors and Prevention, Rehabilitation and Sports Cardiology</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Novo-Nordisk : Clinical trial = SELECT, Principal investigator Lilly : Clinical trial SURPASS-CVOT, Principal investigator</p>
Celutkiene Jelena	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Pfizer : anticoagulation</p> <p>Boehringer-Ingelheim : heart failure</p> <p>Novartis : heart failure</p> <p>Bayer Healthcare : heart failure</p> <p>Astrazeneca : heart failure</p>

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Celutkiene Jelena	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Pfizer : Cardiovascular Disease in Special Populations Boehringer-Ingelheim : Chronic Heart Failure Novartis : Chronic Heart Failure Bayer Healthcare : Chronic Heart Failure Astrazeneca : Chronic Heart Failure</p>
Chieffo Alaide	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Boston Scientific : Coronary Abbott : coronary physiology Abiomed : High Risk PCI and Cardiogenic Shock Edwards Lifesciences : TAVi</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Abiomed : high risk PCI</p>
	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Abiomed : Acute Heart Failure Boston Scientific : Chronic Heart Failure Menarini : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Biosensors : Valvular Heart Disease Medtronic : Valvular Heart Disease</p>

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Christersson Christina	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Boehringer-Ingelheim : Advisory board heart failure Bristol Myers Squibb : Speakers fees Cardiovascular prevention Astra Zeneca : Speakers fees Heart failure Novartis : Speakers fees heart failure and cardiovascular prevention Bayer : Speakers fees valvular diseases</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Novartis : Investigator in clinical trial heartfunction post MI Pfizer : Registerbased study in valvular heart disease</p>
	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bristol Myers Squibb : Atrial Fibrillation (AF) Astra Zeneca : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Novartis : Chronic Heart Failure Bayer : Valvular Heart Disease</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Pfizer : Atrial Fibrillation (AF), Valvular Heart Disease</p>

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Coats Andrew	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <p>Faraday Australia : Acute MI</p> <p>CVRx : Autonomic devices</p> <p>ESN Cleer : Biomarkers</p> <p>Actimed : Cancer</p> <p>CorVia : Device for HFpEF</p> <p>Cardiac Dimensions : Devices for MR</p> <p>Boehringer-Ingelheim : Heart Failure</p> <p>Novartis : Heart Failure</p> <p>Servier : Heart Failure</p> <p>Menarini : Heart Failure</p> <p>Impulse Dynamics : Heart Failure</p> <p>Viatrix : Heart failure</p> <p>Astra Zeneca : Hyperkalaemia</p> <p>Vifor International : Iron deficiency</p> <p>Arena : New drug development in acute heart failure</p> <p>Respicardia : Sleep Apnoea</p>

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry	
Coats Andrew	2022	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <p>Faraday Australia : Acute Coronary Syndromes</p> <p>Astra Zeneca : Chronic Heart Failure</p> <p>Boehringer-Ingelheim : Chronic Heart Failure</p> <p>Novartis : Chronic Heart Failure</p> <p>Servier : Chronic Heart Failure</p> <p>Menarini : Chronic Heart Failure</p> <p>Vifor International : Chronic Heart Failure</p> <p>Respicardia : Chronic Heart Failure</p> <p>ESN Cleer : Chronic Heart Failure</p> <p>Viatrix : Chronic Heart Failure</p> <p>Impulse Dynamics : Device Therapy</p> <p>CVRx : Device Therapy</p> <p>Cardiac Dimensions : Device Therapy</p> <p>CorVia : Device Therapy</p> <p>Actimed : Other</p>
Colivicchi Furio	2021	Nothing to be declared
	2022	Nothing to be declared
Cosentino Francesco	2021	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <p>Boehringer-Ingelheim : Cardiovascular Disease</p> <p>Pfizer : CVD</p> <p>Eli Lilly : CVD and Diabetes</p> <p>Merck Sharp & Dohme : CVD and Diabetes</p> <p>Novo-Nordisk : CVD and Diabetes</p>

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Cosentino Francesco	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Eli Lilly : Cardiovascular Disease in Special Populations, Pharmacology and Pharmacotherapy Novo-Nordisk : Cardiovascular Disease in Special Populations, Pharmacology and Pharmacotherapy Pfizer : Chronic Heart Failure, Cardiovascular Disease in Special Populations, Pharmacology and Pharmacotherapy Merck Sharp & Dohme : Chronic Heart Failure, Cardiovascular Disease in Special Populations, Pharmacology and Pharmacotherapy Boehringer-Ingelheim : Chronic Heart Failure, Risk Factors and Prevention, Cardiovascular Disease in Special Populations</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. ESC Advocacy Committee</p>
Cosyns Bernard	<p>2021</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Abbott : unrestricted research grant in the field of interventional cardiology</p> <p>2022</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Abbott : Unrestricted research grant, PI</p>
Czerny Martin	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. TerumoAortic : Aorta Endospan : Aorta</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). TerumoAortic : Aorta</p> <p>Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease. Healthcare - AORTIC DISEASE, PERIPHERAL VASCULAR DISEASE, STROKE - I am shareholder of a start up named "TEVAR Ltd." which aims at producing a post TEVAR moulding balloon, the company is in the stage of submitting for FDA 520k approval. I am also shareholder of a startup called "Ascense Medical" which aims at producing a stent-graft which is specifically designed for aortic dissection. The company has been founded in 2021 and is currently at a very initial stage.</p>

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Czerny Martin	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Terumo Inc : Cardiovascular Surgery</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Terumo Inc : Cardiovascular Surgery</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. Shareholder of TEVAR Ltd. and Ascense Medical</p>
Deaton Christi	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : heart failure with preserved ejection fraction</p> <hr/> <p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Chronic Heart Failure</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. British Heart Foundation, British Society for Heart Failure, British Cardiovascular Society, American Heart Association</p>
Durkan Maeve	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Novartis : As Board and chair in use of PCSK9 inhibitors in hyperlipidemia / Speaker on CV benefits of emerging DM drugs in emerging arena of CV trials</p> <p>Novo Nordisk : GLP1 analogues in CV health / CVD andCKD burden GLP1 analogues in DM , weight loss</p> <p>Boehringer-Ingelheim : Role of SGLT2 in DM& CHF , both co-dépendantly and independently</p> <p>Astra Zeneca : Role of SGLT2s in DM and also addressing arena of CV and CKD effects</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Ipsen : ECE 2022 Italy</p> <p>Novo-Nordisk : IFSO scientific meeting , USA (obesity ajd metabolic health)</p>

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Durkan Maeve	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Other Boehringer-Ingelheim : Other Novartis : Other Novo Nordisk : Other</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Novo-Nordisk : Other</p>
EL HATTAOUI Mustapha	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Sanofi Aventis : ACS Pfizer : Atrial fibrillation Novartis : Heart failure Actelion : Pulmonary hypertension</p> <hr/> <p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Sanofi Aventis : Acute Coronary Syndromes Pfizer : Atrial Fibrillation (AF) Novartis : Chronic Heart Failure Actelion : Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure</p>

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Falk Volkmar	<p>2021</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <p>Berlin Heart : Advisory</p> <p>Novartis : Consultancy</p> <p>Abbott : Educational Grant for HCP's</p> <p>Edwards Lifesciences : Educational Grant for HCP's</p> <p>Medtronic : Educational Grant for HCP's</p> <p>Cryolife / Jotec : Educational Grant for HCP's</p> <p>Boston Scientific : Study</p> <p>Biotronik : Study</p> <p>Liva Nova : Study</p>
	<p>2022</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <p>Abbott : Other</p> <p>Boston Scientific : Other</p> <p>Edwards Lifesciences : Other</p> <p>Medtronic : Other</p> <p>Novartis : Other</p> <p>Biotronik : Other</p> <p>Liva Nova : Other</p> <p>Berlin Heart : Other</p> <p>Cryolife / Jotec : Other</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology.</p> <p>Affiliations: -DZHK - ETH – Zurich, Dept. Health Science & Technology, Transl. Cardiovascular Technology</p>

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
FERENCE BRIAN A	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Sanofi Aventis : Consultant; Advisory Boards; Honoraria Regeron : Consultant; Advisory Boards; Honoraria Amgen : Consultant; Advisory Boards; Research Grant; Honoraria Merck Sharp & Dohme : Consultant; Advisory Boards; Research Grant; Honoraria Eli Lilly : Consultant; Honoraria Novo-Nordisk : Consultant; Honoraria Krka Pharma : Consultant; Honoraria Mylan : Consultant; Honoraria Ionis : Consultant; Honoraria dalCOR Therapeutics : Consultant; Honoraria Medicines Company : Consultant; Honoraria ; Research Grant Esperion Therapeutics : Consultant; Research Grant; Honoraria Daiichi Sankyo : Daiichi Sankyo</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Esperion Therapeutics : LDL; ACL inhibition Merkck Sharp & Dohme : LDL; NPC1L1 inhibition Novartis : Lp(a); Lp(a) inhibition Amgen : PCSK9 inhibitors; lipids; Lp(a)</p>

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
FERENCE BRIAN A	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <p>Amgen : Risk Factors and Prevention, Research Methodology</p> <p>Daiichi Sankyo : Risk Factors and Prevention, Research Methodology</p> <p>Eli Lilly : Risk Factors and Prevention, Research Methodology</p> <p>Sanofi Aventis : Risk Factors and Prevention, Research Methodology</p> <p>Merck Sharp & Dohme : Risk Factors and Prevention, Research Methodology</p> <p>Novo-Nordisk : Risk Factors and Prevention, Research Methodology</p> <p>Regeron : Risk Factors and Prevention, Research Methodology</p> <p>Esperion Therapeutics : Risk Factors and Prevention, Research Methodology</p> <p>dalCOR Therapeutics : Risk Factors and Prevention, Research Methodology</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <p>Novartis : Mendelian randomization study of lowering LDL by inhibiting PCSK9, Principal Investigator</p> <p>Amgen : Mendelian randomization study of Lp(a), Principal Investigator</p>

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Filippatos Gerasimos	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bayer : Diabetes, CKD Novartis : Heart Failure Servier : Heart Failure Vifor International : Heart Failure Boehringer-Ingelheim : Heart failure, Diabetes</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Impulse Dynamics : Heart Failure Windtree : Heart Failure</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Medtronic : Devices Amgen : Heart Failure European Union : Heart Failure</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. Vice President Onassis Cardiac Surgery Center Past Dean, University of Cyprus Medical School Senior Consulting Editor JACC=HF</p>

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Filipatos Gerasimos	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Novartis : Acute Heart Failure Vifor International : Acute Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Servier : Chronic Heart Failure Bayer : Other</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Windtree : Acute Heart Failure Impulse Dynamics : Chronic Heart Failure</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Medtronic : RESEARCH GRANT, PRINCIPAL INVESTIGATOR European Union : RESEARCH GRANTS, PRINCIPAL INVESTIGATOR</p>
Fisher Miles	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Novo Nordisk : Diabetes treatments Daiichi Sankyo : Lipid lowering in diabetes Astra Zeneca : SGLT2 inhibitors</p> <hr/> <p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Amarin : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Novo-Nordisk : Other</p>

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Fontes Carvalho Ricardo	<p>2021 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Pfizer : anticoagulation Daiichi Sankyo : anticoagulation Astra Zeneca : Diabetes Boehringer-Ingelheim : Diabetes Bial Portela : dislipidemia Amgen : dyslipidemia Novartis : heart failure Servier : heart failure Menarini : hypertension</p> <hr style="border-top: 1px dashed black;"/> <p>2022 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bayer : Atrial Fibrillation (AF) Astra Zeneca : Chronic Heart Failure Servier : Chronic Heart Failure Boehringer-Ingelheim : History of Cardiology, Chronic Heart Failure Bial Portela : Risk Factors and Prevention</p>
Fras Zlatko	<p>2021 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Boehringer-Ingelheim : diabetes mellitus, anticoagulation Amgen : lipid treatment Sanofi Aventis : lipid treatment Novartis : lipids, heart failure</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Novartis : lipidology - lipoprotein (a)</p>

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry	
Fras Zlatko	2022	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Amgen : Risk Factors and Prevention Boehringer-Ingelheim : Risk Factors and Prevention Novartis : Risk Factors and Prevention Sanofi Aventis : Risk Factors and Prevention Novo-Nordisk : Risk Factors and Prevention Krka Pharma : Risk Factors and Prevention</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Novartis : HORIZON Trial; VICTORION-2P Trial, site principal investigator; n</p>
Gotcheva Nina	2021	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Boehringer-Ingelheim : SGLT inhibitors</p>
	2022	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Boehringer-Ingelheim : Chronic Heart Failure</p>
Gungor Baris	2021	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Abbott : Honoraria Amgen : Honoraria Novartis : Honoraria</p>

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry	
Gungor Baris	2022	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Chronic Heart Failure Novartis : Chronic Heart Failure</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Novo-Nordisk : Risk Factors and Prevention</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Boston Scientific : Device Therapy</p>
Hasan Hosam	2021	Nothing to be declared
	2022	Nothing to be declared
Hazarapetyan Lusine Gevorg	2021	Nothing to be declared
	2022	Nothing to be declared
Huikuri Heikki	2021	Nothing to be declared
	2022	Nothing to be declared
Ibanez Borja	2021	Nothing to be declared
	2022	<p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. My center (CNIC) is a public non-profit institution that receives Royalties for the sale of a polypill containing aspirin, ramipril and atorvastatin (trinomia, sincronium). I am not involved in the development I do NOT receive any personal benefit (neither direct nor indirect).</p>
Jaarsma Tiny	2021	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Boehringer-Ingelheim : heart failure</p>
	2022	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Boehringer-Ingelheim : History of Cardiology, Cardiovascular Nursing and Allied Professions</p>

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
James Stefan	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Medtronic : Proctorship</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Clinical trial executive committee Bayer : Clinical trial executive committee Elixir : Clinical trial executive committee jansen : Clinical trial executive committee Amgen : Clinical trial steering committee Novo-Nordisk : Clinical trial steering committee</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Astra Zeneca : Clinical trial Amgen : Clinical trial leadership Elixir : Clinical trial leadership</p>
	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Medtronic : Valvular Heart Disease</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Amgen : Executive committee member, Executive committee member Janssen-Cilag : Executive committee member, Executive committee member Astra Zeneca : Study PI , Principal investigator</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. Swedish medical Association, Swedish cardiac society</p>

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Kelm Malte	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bayer Vital : Cardiology (Industrie-Symposium Essener Herz- und Gefäßtagung) Abiomed : Cardiology (Virtuelles Symposium im Rahmen der 87. Jahrestagung) Kelcon : Cardiology (22nd internationales kardiologisches Symposium) Bayer Vital : Cardiology (ABCD Symposium) Boehringer-Ingelheim : Cardiology (DGK Weiter- und Fortbildungsakademie Online) CTI GmbH : Cardiology (Freiburger Bad Krotzinger Herzkreislauf-Tage) CTI GmbH : Cardiology (Köln Cardiovascular Summit) Diaplan : Heart Failure (Herzinsuffizienzkongress Rheinland)</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Abiomed : Cardiology B.Braun : Cardiology- Medical imaging Microvision Medical : Cardiology-Microcirculation Edwards Lifesciences : Cardiology-TAVI</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology. American Heart Association European Society for Clinical Investigations Deutsche Gesellschaft für Kardiologie - Herz- und Kreislaufforschung e.V. European Society of Cardiology (FESC) Deutschen Gesellschaft für Angiologie - Gesellschaft für Gefäßmedizin e.V. Deutsche Gesellschaft für Ultraschall in der Medizin e.V. Deutsche Hochdruckliga e.V. Deutschen Gesellschaft für Innere Medizin e.V. Deutsche Gesellschaft für Internistische Intensivmedizin und Notfallmedizin Deutsche Gesellschaft für Klinische Pharmakologie und Therapie e.V. Society of Nitric Oxide Research Board Member Deutsche Herzstiftung Member of the Grants Committee, SFB, DFG Member of the Senate Committee, SFB, DFG Scientific Advisory Board Walter-Siegenthaler-Gesell. Founding Member of the Heartcenter Düsseldorf</p>

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Kelm Malte	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <p>Kelcon : Cardiovascular Disease in Special Populations</p> <p>Bayer Vital : Chronic Heart Failure, Acute Heart Failure</p> <p>CTI GmbH : Chronic Heart Failure, Acute Heart Failure</p> <p>Boehringer-Ingelheim : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)</p> <p>Diaplan : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)</p> <p>CTI GmbH : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)</p> <p>Bayer Vital : Other</p>
Khunti Kamlesh	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <p>Abbott : Diabetes</p> <p>Astra Zeneca : Diabetes</p> <p>Bayer : Diabetes</p> <p>Boehringer-Ingelheim : Diabetes</p> <p>Novartis : Diabetes</p> <p>Servier : Diabetes</p> <p>Sanofi Aventis : Diabetes</p> <p>Lilly : Diabetes</p> <p>Amgen Inc : Diabetes</p> <p>Merck Sharp & Dohme : Diabetes</p> <p>Novo-Nordisk : Diabetes</p> <p>NAPP : Diabetes</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <p>Servier : Diabetes</p> <p>Novo-Nordisk : GLP</p> <p>Astra Zeneca : Type 2 Diabetes</p>

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Khunti Kamlesh	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Boehringer-Ingelheim : Hypertension Abbott : Risk Factors and Prevention Astra Zeneca : Risk Factors and Prevention Bayer : Risk Factors and Prevention Novartis : Risk Factors and Prevention Servier : Risk Factors and Prevention Sanofi Aventis : Risk Factors and Prevention Lilly : Risk Factors and Prevention Amgen Inc : Risk Factors and Prevention Merck Sharp & Dohme : Risk Factors and Prevention Novo-Nordisk : Risk Factors and Prevention NAPP : Risk Factors and Prevention</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Astra Zeneca : Impact of exercise training in combination with dapagliflozin on physical function in adults with type 2 diabetes mellitus: a randomised controlled trial. (Dapagliflozin, Exercise, Co-PI</p>

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Kiss Robert Gabor	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Novartis : heart failure Boehringer-Ingelheim : Heart failure, NOACs Amgen Inc : lipids Bayer AG : NOAC Pfizer : NOACs MSD : NOACs Novo-Nordisk : obesity</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Pfizer : NOACs</p>
	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Pfizer : Atrial Fibrillation (AF) Bayer AG : Atrial Fibrillation (AF) MSD : Atrial Fibrillation (AF) Boehringer-Ingelheim : Chronic Heart Failure Novartis : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Amgen Inc : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Novo-Nordisk : Risk Factors and Prevention</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Novartis : Chronic Heart Failure</p>

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Klimiashvili Zurab	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bayer : Anticoagulation Novartis : Heart failure Abbott : Hypertension Berlin Chemie AG : Hypertension Servier : Hypertension, IHD</p> <hr style="border-top: 1px dashed black;"/> <p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : 4 items checked Novartis : 5 items checked Bayer : 6 items checked Servier : Chronic Heart Failure, Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS), Hypertension, Training and Education Berlin Chemie AG : Chronic Heart Failure, Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS), Hypertension, Training and Education Abbott : Hypertension, Risk Factors and Prevention, Training and Education</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. 2023 Guidelines on CVD and Diabetes - Reviewers</p>
Knudsen Eva Cecilie	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Novo-Nordisk : Participated in a program committee. Obesity treatment</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Novo-Nordisk : SELECT study, take part in local patient inclusion and follow up</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Novo-Nordisk : Diabetes care in patients with cardiovascular diseases, participated as a speaker</p>

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Knudsen Eva Cecilie	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Pfizer : Chronic Heart Failure Novo-Nordisk : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Novartis : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Novo-Nordisk : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Novo-Nordisk : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)</p>
Kober Lars	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Heart Failure Bayer : Heart Failure Boehringer-Ingelheim : Heart Failure Novartis : Heart Failure Novo-Nordisk : Heart Failure</p> <hr/> <p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Chronic Heart Failure Bayer : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Novartis : Chronic Heart Failure</p>

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Koskinas Konstantinos	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Amgen : Cardiology Daiichi Sankyo : Cardiology</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Novartis : Cardiology</p>
	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Amgen : Risk Factors and Prevention Daiichi Sankyo : Risk Factors and Prevention Sanofi Aventis : Risk Factors and Prevention</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Novartis : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)</p>
Lautamaki Riikka	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Abbott : Cardiac imaging Bayer : Heart Failure Pfizer : Heart Failure Boehringer-Ingelheim : Heart Failure, Diabetes</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Pfizer : Heart Failure</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Boehringer-Ingelheim : Heart Failure Vifor International : Heart Failure</p>

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Lautamaki Riikka	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Boehringer-Ingelheim : Chronic Heart Failure Roche Diagnostics : Chronic Heart Failure Amgen : European Society of Cardiology</p>
Lewis Basil S	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Idorsia : Antithrombotics Kowa : Lipidology CSL Behring : Lipidology, Secondary prevention</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Kowa : Lipidology</p> <hr/> <p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. CSL Behring : Acute Coronary Syndromes, Pharmacology and Pharmacotherapy Idorsia : Acute Coronary Syndromes, Pharmacology and Pharmacotherapy Janssen R & D : Atrial Fibrillation (AF), Acute Coronary Syndromes, Pharmacology and Pharmacotherapy Anthos : Atrial Fibrillation (AF), Pharmacology and Pharmacotherapy</p>
Libungan Berglind Gerda	<p>2021 Nothing to be declared</p> <hr/> <p>2022 Nothing to be declared</p>
Lochen Maja-Lisa	<p>2021 Nothing to be declared</p>

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry	
Lochen Maja-Lisa	2022	Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Sanofi Aventis : Acute Coronary Syndromes BMS/Pfizer : Atrial Fibrillation (AF) Bayer AG : Atrial Fibrillation (AF)
Magri Caroline Jane	2021	Nothing to be declared
	2022	Nothing to be declared
Mancini Tatiana	2021	Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Sanofi Aventis : diabetes Travel and meeting support from healthcare industry, independent of the above activities. Eli Lilly : Diabetes
	2022	Travel and meeting support from healthcare industry, independent of the above activities. Sanofi Aventis : Other
Martens Fabrice	2021	Nothing to be declared
	2022	Nothing to be declared
Martinka Emil	2021	Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Diabetes (epidemiology, physiology, complications, treatment) Boehringer-Ingelheim : Diabetes (epidemiology, physiology, complications, treatment) Eli Lilly : Diabetes (epidemiology, physiology, complications, treatment) Sanofi Aventis : Diabetes (epidemiology, physiology, complications, treatment) Novo-Nordisk : Diabetes (epidemiology, physiology, complications, treatment) Abbott Nutrition : Diabetes (Nutrition) Worwag : Diabetes, neuropathy

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry	
Martinka Emil	2022	Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Other Boehringer-Ingelheim : Other Eli Lilly : Other Pfizer : Other Sanofi Aventis : Other Novo-Nordisk : Other Abbott Nutrition : Other Worwag : Other
Mcevoy John William	2021	Nothing to be declared
	2022	Nothing to be declared

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Mellbin Linda	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bayer : Cardiology Novartis : Cardiology Orion Pharma : Cardiology Astra Zeneca : Cardiology, Diabetes Boehringer-Ingelheim : Cardiology, Diabetes Novo-Nordisk : Cardiology, Diabetes</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bayer : Cardiology Boehringer-Ingelheim : Cardiology, Diabetes Novo-Nordisk : Cardiology, Diabetes</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Amgen : Cardiology Bayer AG : Cardiology</p> <hr style="border-top: 1px dashed black;"/> <p>2022</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. NovoNordisk : Cardiovascular Disease in Special Populations, Other Astra Zeneca : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS), Acute Coronary Syndromes Amgen : Risk Factors and Prevention Novartis : Risk Factors and Prevention Sanofi Aventis : Risk Factors and Prevention</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Novo-Nordisk : CV Moa trial, Principal Investigator Astra Zeneca : DAPA-MI trial, Principal Investigator Amgen : Lp(a) screening study, Principal investigator</p>
Mghaieth Zghal Fathia	<p>2021</p> <p>Nothing to be declared</p>

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry	
Mghaieth Zghal Fathia	2022	Nothing to be declared
Mihaylova Borislava	2021	<p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Merck Sharp & Dohme : Anacetrapib National Institute for Health Research (UK), Health Technology Assessment Programme : Cost-effectiveness of statin therapy Barts Charity : Digital pathology National Institute for Health Research : Various clinical studies including economic evaluations</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. I am a member of the Editorial Advisory Board of Value in Health (journal). I do not consider this to present any Col.</p>
	2022	<p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Merck Sharp & Dohme : economic analyses alongside a clinical trial, senior health economist Barts Charity : Research project, principal investigator National Institute for Health Research (UK), Health Technology Assessment Programme : Research project, principal investigator Bowel Research UK : research project, principal investigator</p>

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Milicic Davor	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <p>Novo-Nordisk : Antidiabetics</p> <p>Alcaloid AD Skopje : Antihypertensive medications</p> <p>PLIVA : Antihypertensive medications</p> <p>Krka Pharma : Antihypertensives</p> <p>Astra Zeneca : Antithrombotics in ACS</p> <p>Novartis : ARNI</p> <p>Roche Diagnostics : Biomarkers</p> <p>Abbott : LVAD</p> <p>Servier : Microvascular angina</p> <p>Bayer : NOACs</p> <p>Pfizer : NOACs</p> <p>Boehringer-Ingelheim : NOACs, SGLT-2 inhibitors</p> <p>Amgen : PCSK-9 inhibitors</p> <p>Sanofi Aventis : PCSK-9 inhibitors</p>

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Milicic Davor	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Amgen : Pharmacology and Pharmacotherapy Astra Zeneca : Pharmacology and Pharmacotherapy Bayer : Pharmacology and Pharmacotherapy Boehringer-Ingelheim : Pharmacology and Pharmacotherapy Novartis : Pharmacology and Pharmacotherapy Pfizer : Pharmacology and Pharmacotherapy Servier : Pharmacology and Pharmacotherapy Novo-Nordisk : Pharmacology and Pharmacotherapy Krka Pharma : Pharmacology and Pharmacotherapy PLIVA : Pharmacology and Pharmacotherapy Berlin chemie menarini : Pharmacology and Pharmacotherapy Swixx : Pharmacology and Pharmacotherapy</p>
Mindham Richard	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Imperial College, London : ONCE-OFF Honorarium, 2019, non-recurring, less than GB£900/€1000, passed in full to UK charity, CardiomyopathyUK</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. I have a pension and savings held in shares and funds. I do not control which shares are bought and I do not know whether any of them are invested in healthcare organisations as the shares are managed by a fund manager.</p> <hr/> <p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. PASSpaces. http://passpaces.co.uk/. PASSpaces tutors young British doctors to help them pass their medical examinations. I "act" as a patient, permitting the trainee to take a patient history. : Training and Education</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. European Society of Cardiology. Payment of hotel, travel and meals to attend or speak at ESC conferences. : European Society of Cardiology</p>

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Mindham Richard	<p>2022</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. I support the British charity CardiomyopathyUK, https://www.cardiomyopathy.org.uk/. I make small financial contributions to support their activities. I support the British charity Pumping Marvellous, https://pumpingmarvellous.org/. I make no financial contributions to the charity's activities. I am a member of the Coalition for Reducing Bureaucracy in Clinical Trials, https://bureaucracyincts.eu/. The Coalition is a collection of researchers, clinicians and patients which advocates for the reduction of bureaucracy in clinical trials, chiefly in the EU. I have no financial interest in the Coalition.</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. I have savings and pensions held in shares. The shares are managed by a financial adviser; I do not not control the purchase & sale of shares and I do not know whether any shares are in medical companies.</p>
Mirrakhimov Erkin	<p>2021 Nothing to be declared</p> <p>2022 Nothing to be declared</p>
Mitchenko Olena	<p>2021 Nothing to be declared</p> <p>2022 Nothing to be declared</p>
Neubeck Lis	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Pfizer : Atrial Fibrillation (AF),</p>
Nielsen Jens Cosedis	<p>2021 Nothing to be declared</p> <p>2022</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. Have received research funding to my institution for independent research from the Danish Heart Foundation and the Novo Nordisk Foundation.</p>
Parati Gianfranco	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Servier : Honoraria for lecture on COVID 19 and cardiovascular risk Merk Serono : Honoraria for lecture on European Hypertension Guidelines OMRON Healthcare : Honoraria for lectures on Blood Pressure Measurement Bayer : Honoraria for lectures on Hypertension Fidia : Honoraria for lectures on Sleep Disordered Breathing and Cardiovascular Diseases</p>

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry	
Parati Gianfranco	2022	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Daiichi Sankyo : Hypertension Merck Sharp & Dohme : Hypertension OMRON Healthcare : Hypertension Somnomedics : Hypertension</p>
Pasquet Agnes A	2021	<p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Daiichi Sankyo : general cardiology Servier : general cardiology Philips : imaging</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology. member of the Belgian Society of Cardiology</p>
	2022	<p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Philips : Echocardiography, Interventional Cardiology Daiichi Sankyo : Hypertension Servier : Other</p>
Patrono Carlo	2021	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Tremeau : Clinical development of rofecoxib for haemophilic arthritis Eli Lilly : Novel anti diabetic drugs and cardiovascular disease</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Menarini Foundation : International Symposium on Cardiometabolic Risk and Vascular Disease, Karolinska Institutet</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Bayer : Chemoprevention of colorectal cancer</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. I chair the Scientific Advisory Board of the International Aspirin Foundation, a non-profit organization</p>

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Patrono Carlo	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Eli Lilly : Risk Factors and Prevention</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Bayer : Investigating the mechanism of action of aspirin in the chemoprevention of colorectal cancer, Co-investigator</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. I have chaired (until October 2022) the Scientific Advisory Board of the International Aspirin Foundation</p>
Petersen Steffen Erhard	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Circle Cardiovascular Imaging, Inc : Cardiac MRI and CT analysis and reporting software</p> <p>Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease. Healthcare - IMAGING - Circle Cardiovascular Imaging Inc., Calgary, Canada (25,000 shares at Canadian dollars \$1.50 each.)</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology. Membership British Cardiovascular Society, Royal College of Physicians, British Medical Association.</p> <hr/> <p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Circle Cardiovascular Imaging, Inc : Cardiac Magnetic Resonance (CMR), Cardiac Computed Tomography (CT)</p> <p>Research funding (personal) from healthcare industry. Neosoft, LLC : Establishment of healthy reference ranges of cardiac volumes using CMR and Neosoft's SuiteHeart software, Principal investigator</p>
Piepoli Massimo Francesco	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Servier : Speaker fee, consultancy Boehringer Ingelheim : Speaker fee, consultancy</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. CHF Solutions : Aquapheresis Therapy in heart failure</p>

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry	
Piepoli Massimo Francesco	2022	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Novo Nordisk : Cardiovascular Disease in Special Populations Boehringer Ingelheim : Chronic Heart Failure Astra-Zeneca : Chronic Heart Failure Menarini, : Chronic Heart Failure</p>
Prescott Eva	2021	Nothing to be declared
	2022	Nothing to be declared
Rakishveva Amina	2021	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bayer : Atrial Fibrillatuion Novartis : Heart Failure</p>
	2022	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Chronic Heart Failure Novartis : Chronic Heart Failure Roche Diagnostics : Chronic Heart Failure</p>
Rossello Francisco Javier	2021	Nothing to be declared
	2022	Nothing to be declared

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Rossing Peter	<p>2021</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : diabetes and chronic kidney disease Eli Lilly : diabetes and chronic kidney disease Astellas : diabetes and chronic kidney disease Sanofi Aventis : diabetes and kidney disease Novo-Nordisk : diabetes and kidney disease Boehringer-Ingelheim : diabetic kidney disease Gilead : diabetic kidney disease Bayer AG : Diabetic kidney disease</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Astra Zeneca : diabetic kidney disease Novo-Nordisk : diabetic kidney disease</p>
	<p>2022</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Other Boehringer-Ingelheim : Other Eli Lilly : Other Sanofi Aventis : Other Gilead : Other Novo-Nordisk : Other Bayer AG : Other Abbott Laboratories : Risk Factors and Prevention</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Bayer Healthcare : investigator initiated study of CKD in diabetes in Denmark, PI Astra Zeneca : support investigator initiated study of sglT2i effect on urinary proteomics, PI Novo-Nordisk : support investigator initiated study on sglT2 +GLP1 in diabetic CKD, PI</p>

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry	
Rustamova Yasmin	2021	Nothing to be declared
	2022	Nothing to be declared
Ryden Lars	2021	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Novo-Nordisk : `Glucose lowering drugs and cardiovascular disease Bayer : Coronary artery disease and prevention Boehringer-Ingelheim : Diabetes and cardiovascular disease</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Boehringer-Ingelheim : Diabetes and coronary artery disease</p> <p>Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease. Healthcare - OTHER - All my income declare above is paid to my company Propactus Ltd which is registered for education and consulting in the area of cardiovascular disease. It is under the control of external revision.</p>
	2022	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bayer : Congenital Heart Disease and Paediatric Cardiology Eli Lilly : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Novo-Nordisk : Pharmacology and Pharmacotherapy Boehringer-Ingelheim : Risk Factors and Prevention</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. I have a company Propactus Ltd to which all my honoraria are transferred. It works in the health care sector and is under the control of official accounting.</p>

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Saade Georges	<p>2021</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <p>Astra Zeneca : Speaker fees</p> <p>Bayer : Speaker fees</p> <p>Boehringer-Ingelheim : Speaker fees</p> <p>Novartis : Speaker fees</p> <p>Pfizer : Speaker fees</p> <p>Servier : Speaker fees</p>
	<p>2022</p> <p>Nothing to be declared</p>
Schou Morten	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <p>Astra Zeneca : Lecture Fee</p> <p>Boehringer-Ingelheim : Lecture Fee</p> <p>Novartis : Lecture Fee</p> <p>Novo-Nordisk : Lecture Fee</p>
	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <p>Astra Zeneca : Chronic Heart Failure</p> <p>Boehringer-Ingelheim : Chronic Heart Failure</p> <p>Novartis : Chronic Heart Failure</p> <p>Novo-Nordisk : Chronic Heart Failure</p> <p>Travel and meeting support from healthcare industry, independent of the above activities.</p> <p>Boehringer-Ingelheim : Chronic Heart Failure</p>

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Siasos Gerasimos	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Boehringer-Ingelheim : Diabetes Novo-Nordisk : Diabetes</p> <p>Research funding (personal) from healthcare industry. Boehringer-Ingelheim : Diabetes Novo-Nordisk : Diabetes</p>
	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Boehringer-Ingelheim : Other</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Boehringer-Ingelheim : Other</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Novo-Nordisk : CLINICAL TRIAL, principal investigator</p>
Sokolovic Sekib	<p>2021</p> <p>Nothing to be declared</p>
	<p>2022</p> <p>Nothing to be declared</p>
Standl Eberhard	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Lecturing fee Boehringer-Ingelheim : Lecturing fee Berlin Chemie AG : Lecturing fee Novo-Nordisk : Lecturing fee</p>
	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Chronic Heart Failure, Risk Factors and Prevention Berlin Chemie AG : Other Boehringer-Ingelheim : Risk Factors and Prevention, Pharmacology and Pharmacotherapy Novo-Nordisk : Risk Factors and Prevention, Pharmacology and Pharmacotherapy</p>

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Tokgozoglulale	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <p>Pfizer : Anticoagulation</p> <p>Novo-Nordisk : Diabetes</p> <p>Abbott : Lipids</p> <p>Amgen : Lipids</p> <p>Novartis : Lipids</p> <p>Sanofi Aventis : Lipids</p> <p>Recordati International : Lipids</p> <p>Daiichi-Sankyo : Lipids</p> <p>Mylan : Lipids</p> <p>Actelion/Jansen : Pulmonary hypertension</p> <p>Bayer : Pulmonary hypertension, heart failure</p>
	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <p>Abbott : Risk Factors and Prevention</p> <p>Amgen : Risk Factors and Prevention</p> <p>Astra Zeneca : Risk Factors and Prevention</p> <p>Bayer : Risk Factors and Prevention</p> <p>Novartis : Risk Factors and Prevention</p> <p>Pfizer : Risk Factors and Prevention</p> <p>Sanofi Aventis : Risk Factors and Prevention</p> <p>Merck Sharp & Dohme : Risk Factors and Prevention</p> <p>Novo-Nordisk : Risk Factors and Prevention</p> <p>Recordati International : Risk Factors and Prevention</p> <p>Daiichi-Sankyo : Risk Factors and Prevention</p> <p>Mylan : Risk Factors and Prevention</p>

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry	
Touyz Rhian	2021	Nothing to be declared
	2022	Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. Editor-in-Chief, Hypertension, American Heart Association Member of guideline committee on 'Aldosterone', Endocrine Society
Trigulova Raisa	2021	Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. scientific interest
	2022	Nothing to be declared
Trusinskis Karlis	2021	Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Boehringer-Ingelheim : dabigatran, empagliflozin Novo-Nordisk : liraglutide, semaglutide Berlin Menarini : olmesartan, nebivolol Biotronik : orsiro, magmaris Servier : perindopril, drug single pill combinations Bayer : rivaroxabane Astra Zeneca : Ticagrelor, dapagliflozin
	2022	Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Biotronik : Arrhythmias, General Bayer : Atrial Fibrillation (AF) Astra Zeneca : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Servier : Hypertension Berlin Menarini : Hypertension Novo-Nordisk : Risk Factors and Prevention
Tundybayeva Meiramgul	2021	Nothing to be declared

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry	
Tundybayeva Meiramgul	2022	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Roche Diagnostics : Chronic Heart Failure, Acute Coronary Syndromes, Hypertension Novartis : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Abbott : Hypertension Servier : Hypertension, Risk Factors and Prevention</p>
van de Borne Philippe	2021	<p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Novartis : Education - cardiovascular prevention Sanofi Aventis : Education - cardiovascular prevention Bayer Healthcare : Education - cardiovascular prevention Amgen : Education - cardiovascular prevention, Advisory board</p>
	2022	Nothing to be declared
Viigimaa Margus	2021	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Diabetes Boehringer-Ingelheim : Diabetes Novo-Nordisk : Diabetes Sanofi Aventis : Diabetes, lipids Menarini : Hypertension Amgen : Lipids</p>

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Viigimaa Margus	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Amgen : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Sanofi Aventis : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Menarini : Hypertension Novartis : Risk Factors and Prevention Novo-Nordisk : Risk Factors and Prevention</p>
Vinereanu Dragos	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Boehringer-Ingelheim : Atrial Fibrillation, heart failure Servier : Hypertension, Heart Failure</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Pfizer : Atrial fibrillation Boehringer-Ingelheim : Atrial fibrillation, heart failure Sanofi Aventis : Dyslipidemia Novartis : Heart failure Vifor International : Heart failure Terapia : Hypertension, Coronary syndromes</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Novartis : Clinical trial ACS Dalcor : Clinical trial CCS Chiltern : Clinical trial heart failure, ACS Amgen : Clinical trial, Dyslipidemia PPD Global : Clinical trial, heart failure</p>

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Vinereanu Dragos	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Servier : Hypertension Actelion : Pharmacology and Pharmacotherapy Amgen : Risk Factors and Prevention</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Pfizer : Atrial Fibrillation (AF) Boehringer-Ingelheim : Chronic Heart Failure Terapia : Hypertension Novartis : Pharmacology and Pharmacotherapy Sanofi Aventis : Pharmacology and Pharmacotherapy Amgen Inc : Pharmacology and Pharmacotherapy</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Servier : European Society of Cardiology</p>
Visseren Frank Lj	<p>2021</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Amgen : Familial Dysbetalipoproteinemia</p> <hr/> <p>2022</p> <p>Nothing to be declared</p>

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Volpe Massimo	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Daiichi Sankyo : Bempedoic acid Astra Zeneca : Dapaglifozin Kalos Medical : Denervation Device Novartis : Entresto Amarin : Icosapent Ethyl Sanofi Pasteur : Influenza Vaccine Menarin international : Olmesartan, Zofenopril, Nebivolol Amgen : PCSK9i Servier : Perindopril, Indapamide, Amlodipina Bayer AG : Rivaroxaban</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Medtronic : Renal Denervation Device</p>
	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Amarin : Pharmacology and Pharmacotherapy</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Servier : Risk Factors and Prevention</p>

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Vrablik Michal	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Novartis : cardiovascular prevention Mylan : lipid metabolism Amgen : lipid metabolism, CVD prevention Servier : lipid metabolism, CVD prevention Sanofi Aventis : lipid metabolism, CVD prevention Merck Sharp & Dohme : lipid metabolism, CVD prevention Krka Pharma : lipid metabolism, preventive cardiology</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Pfizer : cardiovascular Sanofi Aventis : lipid metabolism</p>
	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Amgen : Risk Factors and Prevention Novartis : Risk Factors and Prevention Servier : Risk Factors and Prevention Sanofi Aventis : Risk Factors and Prevention Merck Sharp & Dohme : Risk Factors and Prevention Krka Pharma : Risk Factors and Prevention Mylan : Risk Factors and Prevention</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Novartis : research grant to Czech Atherosclerosis Society, chief investigator</p>
Vrints Christiaan Jm	<p>2021</p> <p>Nothing to be declared</p>
	<p>2022</p> <p>Nothing to be declared</p>

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Wheatcroft Stephen	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bayer : Anticoagulation Novo-Nordisk : Diabetes Boehringer-Ingelheim : Diabetes, heart failure Lilly : Diabetes, heart failure Astra Zeneca : Diabetes, heart failure, chronic kidney disease</p> <p>Employment in healthcare industry (including part time) during the year for which you are declaring. Honorary consultant cardiologist Leeds Teaching Hospitals NHS Trust UK</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology. Chair of CaReMe UK</p>
	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Boehringer-Ingelheim : Chronic Heart Failure, Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS), Risk Factors and Prevention Bayer : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Astra Zeneca : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS), Chronic Heart Failure, Risk Factors and Prevention Lilly : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS), Risk Factors and Prevention</p>
Witkowski Adam	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Boston Scientific : coronary stents, IVUS, Accurate aortic valves (TAVI), Watchman (LAO) Medtronic : Evolute aortic valves (TAVI) Edwards Lifesciences : Sapien aortic valves (TAVI)</p>

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Witkowski Adam	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Boston Scientific : Device Therapy Edwards Lifesciences : Device Therapy Medtronic : Device Therapy</p>
Zafir Barak	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Novartis : Lipids Sanofi Aventis : Lipids and cardiovascular risk</p>
	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Novartis : Risk Factors and Prevention Sanofi Aventis : Risk Factors and Prevention</p>

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Zirlik Andreas	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Daiichi Sankyo : anticoagulation Bristol Myers Squibb : Anticoagulation and high risk management Novo-Nordisk : Diabetes, GLP-1A, Inflammation and atherosclerosis Pfizer : High risk management Sanofi Aventis : Lipid and high risk management Amgen : Lipid and high risk management, atherosclerosis Novartis : Lipid management and atherosclerosis, executive board member Victorion2-Prevent Abbott : Mitral and tricuspid disease and interventional treatment Edwards Lifesciences : Mitral and tricuspid disease and interventional treatment Bayer Healthcare : NOACs, high risk management, anticoagulation in Affig and atherosclerosis Boehringer-Ingelheim : SGLT-2i, diabetes and inflammation, atherosclerosis Astra Zeneca : SGLT-2i, platelet inhibition, atherosclerosis Medtronic : TAVI</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Abbott : CV Congresses Daiichi Sankyo : CV Congresses Medtronic : CV Congresses Novartis : CV Congresses Bayer Healthcare : CV Congresses</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Edwards Lifesciences : Structural Heart Management</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology. German Society of Cardiology, Austrian Society of Cardiology, German Atherosclerosis Society, Austrian Atherosclerosis Society, American Heart Association, American College of Cardiology</p>

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Zirlik Andreas	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Daiichi Sankyo : Atrial Fibrillation (AF) Bayer Healthcare : Atrial Fibrillation (AF) Bristol Myers Squibb : Atrial Fibrillation (AF), Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Boehringer-Ingelheim : Chronic Heart Failure Novartis : Chronic Heart Failure, Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Amgen : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Pfizer : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Sanofi Aventis : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Novo-Nordisk : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Astra Zeneca : Interventional Cardiology, Chronic Heart Failure Abbott : Valvular Heart Disease Edwards Lifesciences : Valvular Heart Disease Medtronic : Valvular Heart Disease</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Daiichi Sankyo : Atrial Fibrillation (AF) Bayer Healthcare : Atrial Fibrillation (AF) Novartis : Chronic Heart Failure Abbott : Valvular Heart Disease Medtronic : Valvular Heart Disease</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Edwards Lifesciences : Grant to establish a Structural Heart Manager, PI</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry	
Arbelo Elena	2021	Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Biosense Webster : Atrial fibrillation
	2022	Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Biosense Webster : Atrial Fibrillation (AF)
Baigent Colin	2021	Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Boehringer-Ingelheim : Renal disease
	2022	Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Boehringer Ingelheim : Grant to the University of Oxford for the EMPA-KIDNEY trial, Co-PI
Borger Michael A	2021	Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Cryolife : aortic surgery Abbott : heart valve therapy Edwards Lifesciences : heart valve therapy Medtronic : heart valve therapy
	2022	Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Artivion (formerly CryoLife) : Diseases of the Aorta Abbott : Valvular Heart Disease Edwards Lifesciences : Valvular Heart Disease Medtronic : Valvular Heart Disease
Buccheri Sergio	2021	Nothing to be declared
	2022	Nothing to be declared
Ibanez Borja	2021	Nothing to be declared

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Ibanez Borja	<p>2022</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. My center (CNIC) is a public non-profit institution that receives Royalties for the sale of a polypill containing aspirin, ramipril and atorvastatin (trinomia, sincronium). I am not involved in the development I do NOT receive any personal benefit (neither direct nor indirect).</p>
James Stefan	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Medtronic : Proctorship</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Clinical trial executive committee Bayer : Clinical trial executive committee Elixir : Clinical trial executive committee jansen : Clinical trial executive committee Amgen : Clinical trial steering committee Novo-Nordisk : Clinical trial steering committee</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Astra Zeneca : Clinical trial Amgen : Clinical trial leadership Elixir : Clinical trial leadership</p> <hr/> <p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Medtronic : Valvular Heart Disease</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Amgen : Executive committee member, Executive committee member Janssen-Cilag : Executive committee member, Executive committee member Astra Zeneca : Study PI , Prinicpal investigator</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. Swedish medical Association, Swedish cardiac society</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Kober Lars	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Heart Failure Bayer : Heart Failure Boehringer-Ingelheim : Heart Failure Novartis : Heart Failure Novo-Nordisk : Heart Failure</p>
	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Chronic Heart Failure Bayer : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Novartis : Chronic Heart Failure</p>
Koskinas Konstantinos	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Amgen : Cardiology Daiichi Sankyo : Cardiology</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Novartis : Cardiology</p>
	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Amgen : Risk Factors and Prevention Daiichi Sankyo : Risk Factors and Prevention Sanofi Aventis : Risk Factors and Prevention</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Novartis : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry	
Mcevoy John William	2021	Nothing to be declared
	2022	Nothing to be declared
Mihaylova Borislava	2021	<p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Merck Sharp & Dohme : Anacetrapib National Institute for Health Research (UK), Health Technology Assessment Programme : Cost-effectiveness of statin therapy Barts Charity : Digital pathology National Institute for Health Research : Various clinical studies including economic evaluations</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. I am a member of the Editorial Advisory Board of Value in Health (journal). I do not consider this to present any Col.</p>
	2022	<p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Merck Sharp & Dohme : economic analyses alongside a clinical trial, senior health economist Barts Charity : Research project, principal investigator National Institute for Health Research (UK), Health Technology Assessment Programme : Research project, principal investigator Bowel Research UK : research project, principal investigator</p>
Mindham Richard	2021	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Imperial College, London : ONCE-OFF Honorarium, 2019, non-recurring, less than GB£900/€1000, passed in full to UK charity, CardiomyopathyUK</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. I have a pension and savings held in shares and funds. I do not control which shares are bought and I do not know whether any of them are invested in healthcare organisations as the shares are managed by a fund manager.</p>
	2022	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. PASSpaces. http://passpaces.co.uk/. PASSpaces tutors young British doctors to help them pass their medical examinations. I "act" as a patient, permitting the trainee to take a patient history. : Training and Education</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. European Society of Cardiology. Payment of hotel, travel and meals to attend or speak at ESC conferences. : European Society of Cardiology</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Mindham Richard	<p>2022</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. I support the British charity CardiomyopathyUK, https://www.cardiomyopathy.org.uk/. I make small financial contributions to support their activities. I support the British charity Pumping Marvellous, https://pumpingmarvellous.org/. I make no financial contributions to the charity's activities. I am a member of the Coalition for Reducing Bureaucracy in Clinical Trials, https://bureaucracyincts.eu/. The Coalition is a collection of researchers, clinicians and patients which advocates for the reduction of bureaucracy in clinical trials, chiefly in the EU. I have no financial interest in the Coalition.</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. I have savings and pensions held in shares. The shares are managed by a financial adviser; I do not not control the purchase & sale of shares and I do not know whether any shares are in medical companies.</p>
Neubeck Lis	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Pfizer : Atrial fibrillation</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology. Medical advisor to the Atrial Fibrillation Alliance</p> <hr/> <p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Pfizer : Atrial Fibrillation (AF),</p>
Nielsen Jens Cosedis	<p>2021</p> <p>Nothing to be declared</p> <hr/> <p>2022</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. Have received research funding to my institution for independent research from the Danish Heart Foundation and the Novo Nordisk Foundation.</p>
Pasquet Agnes A	<p>2021</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Daiichi Sankyo : general cardiology Servier : general cardiology Philips : imaging</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology. member of the Belgian Society of Cardiology</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Pasquet Agnes A	<p>2022 Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Philips : Echocardiography, Interventional Cardiology Daiichi Sankyo : Hypertension Servier : Other</p>
Prescott Eva	<p>2021 Nothing to be declared</p>
	<p>2022 Nothing to be declared</p>
Rakisheva Amina	<p>2021 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bayer : Atrial Fibrillatuion Novartis : Heart Failure</p>
	<p>2022 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Chronic Heart Failure Novartis : Chronic Heart Failure Roche Diagnostics : Chronic Heart Failure</p>
Rocca Bianca	<p>2021 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bayer AG : CV prevention in COVID pandemics SOBI : platelet growth factor Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Bayer AG : anticoagulant (rivaroxaban)</p>
	<p>2022 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Aboca SRL : Other Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Bayer AG : study on low dose rivaroxaban, Chief investigator</p>
Rossello Francisco Javier	<p>2021 Nothing to be declared</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry	
Rossello Francisco Javier	2022	Nothing to be declared
Vaartjes Ilonca	2021	Nothing to be declared
	2022	Nothing to be declared
Vrints Christiaan Jm	2021	Nothing to be declared
	2022	Nothing to be declared
Witkowski Adam	2021	Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Boston Scientific : coronary stents, IVUS, Accurate aortic valves (TAVI), Watchman (LAO) Medtronic : Evolute aortic valves (TAVI) Edwards Lifesciences : Sapien aortic valves (TAVI)
	2022	Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Boston Scientific : Device Therapy Edwards Lifesciences : Device Therapy Medtronic : Device Therapy
Zeppenfeld Katja	2021	Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Biosense Webster : Research electrophysiology
	2022	Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Biosense Webster : Ventricular Arrhythmias and Sudden Cardiac Death (SCD) Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Biosense Webster : investigator initiated research, PI